Drawing for SPRECEL

USPTO serial 78885291

SPRECEL

Reviewed by CopyMark Law Group

Status 605
Filing date
Status date
Registration date
Examiner
FARRELL, ANNE M
Law office
PETITIONS OFFICE

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SPRECEL?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Nadine P. Flynn

NADINE P FLYNN BRISTOL-MYERS SQUIBB COMPANY345 PARK AVENEW YORK, NY 10154-0004UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for human use for the treatment and prevention of obesity, diabetes, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, and pharmaceutical antibodies; diagnostic pharmaceutical preparations for human use; diagnostic imaging and ultrasound contrast agents for human use; pharmaceutical preparations for human use for identifying and diagnosing cardiovascular diseases and conditions; diagnostic pharmaceutical preparations for human use, namely, preparations for increasing the heart rate for diagnostic purposesABANDONED

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 10, 2007MAB5ABANDONMENT NOTICE MAILED - AFTER PUBLICATION
Oct 10, 2007ABN5ABANDONMENT - AFTER PUBLICATION
Oct 5, 2007ETOPEXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Sep 19, 2007EXARTEAS EXPRESS ABANDONMENT RECEIVED
Jun 18, 2007ETOFEXTENSION OF TIME TO OPPOSE RECEIVED
May 22, 2007PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 2, 2007NPUBNOTICE OF PUBLICATION
Mar 21, 2007PREVLAW OFFICE PUBLICATION REVIEW COMPLETED
Mar 21, 2007ALIEASSIGNED TO LIE
Feb 27, 2007CNEAEXAMINERS AMENDMENT MAILED
Feb 26, 2007CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Feb 26, 2007XAECEXAMINER'S AMENDMENT ENTERED
Feb 26, 2007CNEAEXAMINERS AMENDMENT -WRITTEN
Jan 31, 2007TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Jan 30, 2007CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 30, 2007TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 29, 2006CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 29, 2006CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 27, 2006DOCKASSIGNED TO EXAMINER
May 23, 2006NWAPNEW APPLICATION ENTERED

Frequently asked questions

Related guidance